## EVALUATION

Evaluation of patients with documented hypertension has three objectives:

- To identify known causes of high blood pressure
- To assess the presence or absence of target organ damage
- To identify other cardiovascular risk factors or concomitant disorders that may define prognosis and guide treatment

Data for evaluation is acquired through medical history, physical examination, laboratory tests, and other special diagnostic procedures

## Medical history

- Duration and level of elevated blood pressure, if known
- Symptoms of coronary artery disease (CAD), heart failure, cerebrovascular disease, peripheral vascular disease and CKD
- Diabetes mellitus, dyslipidaemia, obesity, gout, sexual dysfunction and other co-morbid conditions
- Family history of high blood pressure, obesity, premature CAD and stroke, dyslipidaemia and diabetes
- Symptoms suggesting secondary causes of hypertension
- History of smoking or tobacco use, physical activity, dietary assessment including intake of sodium, alcohol, saturated fat and caffeine
- Socioeconomic status, professional and educational levels
- History of use / intake of all prescribed and over-the-counter medications, herbal remedies, licorice (Yashtimadhu/Jestamadha), illicit drugs, corticosteroids, NSAIDs, nasal drops. These may raise blood pressure or interfere with the effectiveness of antihypertensive drugs
- History of oral contraceptive use and hypertension during pregnancy
- History of previous antihypertensive therapy, including adverse effects experienced, if any
- Psychosocial and environmental factors


## Physical examination

- Record three blood pressure readings separated by 2 minutes, with the patient either supine or sitting position and after standing for at least 2 minutes.
- Record height, weight and waist circumference.
- Examine the pulse and the extremities for delayed or absent femoral and peripheral arterial pulsations, bruits and pedal oedema.
- Look for arcus senilis, acanthosis nigricans, xanthelasma and xanthomas.
- Examine the neck for carotid bruits, raised JVP or an enlarged thyroid gland.
- Examine the heart for abnormalities in rate and rhythm, location of apex beat, fourth heart sound and murmurs.
- Examine the lungs for rales and rhonchi.
- Examine the abdomen for bruits, enlarged kidneys, masses and abnormal aortic pulsation.
- Examine the optic fundus and do a neurological assessment.


## INDIAN HYPERTENSION GUIDELINES-II

## Laboratory investigations

- Routine:
- Urine examination for protein and glucose and microscopic examination for RBCs and other sediments.
- Haemoglobin, fasting blood glucose, serum creatinine, potassium and total cholesterol
- 12-lead electrocardiogram
- Additional investigations in special circumstances can include
- Fasting lipid profile and uric acid
- Echocardiogram
- Other specific tests to rule out secondary causes of hypertension where there is a high index of suspicion are described under "secondary hypertension".
- At the present state, tests for HS-CRP, serum homocysteine levels and microalbuminuria are not recommended for routine clinical use.
- The cost of investigations in the context of the needs of an individual patient and resources available is an important consideration. In patients with essential hypertension where there is a resource crunch, one may be required to initiate therapy without carrying out any laboratory investigations.


## Factors influencing risk

Before initiating therapy, patients' overall risk should be assessed considering the presence or absence of additional risk factors; extent of target organ damage and other associated clinical conditions.

## Table 5: Factors influencing risk of cardiovascular disease

| Risk factors for coronary artery disease (RF) | Target organ damage (TOD) | Associated clinical conditions (ACC) |
| :---: | :---: | :---: |
| - Age > 55 years <br> - Male sex <br> - Post-menopausal women <br> - Smoking and tobacco use <br> - Diabetes mellitus <br> - Family history of premature CAD (Males < 55 years, Female < 65 years) <br> - Increased Waist hip ratio, High LDL or total cholesterol, Low HDL cholesterol and High triglycerides <br> - High sensitivity C-reactive protein (HS-CRP) and homocysteine levels might evolve as markers for high risk of vascular damage <br> - Estimated GFR <60 mL/min | - Left ventricular hypertrophy detected by ECG and/or echocardiogram <br> - Microalbuminuria/ proteinuria and/or elevation of serum creatinine (1.2-2.0 mg/dl) <br> - Urinary ACR (albumin creatinine ratio) <br> - Ultrasound or radiological evidence of atherosclerotic plaques in the carotids <br> - Hypertensive retinopathy | - Cerebrovascular disease <br> - Ischemic stroke <br> - Cerebral haemorrhage <br> - Transient ischemic attack <br> - Heart disease <br> - Myocardial infarction <br> - Angina <br> - Coronary revascularization <br> - Congestive heart failure <br> - Renal disease <br> - Diabetic nephropathy <br> - Renal failure (serum creatinine > $2.0 \mathrm{mg} / \mathrm{dl}$ ) <br> - Vascular disease <br> - Peripheral arterial disease including non-specific aortoarteritis <br> - Aortic dissection <br> - Advanced hypertensive retinopathy <br> - Haemorrhages or exudates <br> - Papilledema |

## INDIAN HYPERTENSION GUIDELINES-II

The prognosis of these patients and the choice and need for urgency of therapy, will be dependent on the overall risk stratification (Table 6)

Hyperhomocysteinemia (hyperHcy) has been associated with hypertension and higher CV risk. ${ }^{24,25,26}$ Whether the relation between total plasma homocysteine (tHcy) and cardiovascular disease is causal or not remains controversial. ${ }^{27,28}$ Large prospective controlled trials in patients with concomitant hypertension and hyperHcy should be conducted to evaluate the impact of tHcy lowering therapy on endpoints related to hypertension and its complications.

|  |  | Blood pressure (mm Hg) |  |  |
| :---: | :---: | :---: | :---: | :---: |
| \% | Other risk factors and disease history | Stage 1 | Stage 2 | Stage 3 (severe hypertension) |
|  |  | SBP 140-159 or DBP 90-99 | $\begin{aligned} & \text { SBP 160-179 } \\ & \text { or DBP 100-109 } \end{aligned}$ | SBP $\geq 180$ or $\mathrm{DBP} \geq 110$ |
| 1 | No other risk factors | Low risk | Medium risk | High risk |
| II | 1-2 risk factors ${ }^{\text {a }}$ | Medium risk | Medium risk | Very high risk |
| III | 3 or more risk factors or TOD ${ }^{\text {b }}$ or diabetes | High risk | High risk | Very high risk |
| IV | $\mathrm{ACC}^{\circ}$ | Very high risk | Very high risk | Very high risk |

Risk strata (typical 10 year risk of stroke or myocardial infarction):
Low risk = Less than 15\%
Medium risk = about 15-20\%
High risk = about 20-30\%
Very high risk $=30 \%$ or more
${ }^{\text {a }}$ See Table 5
${ }^{\mathrm{b}}$ TOD: Target Organ Damage see Table 5
${ }^{\text {c }}$ ACC: Associated clinical conditions, including clinical cardiovascular disease or renal disease see Table 5

